|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
WednesdayExploratory analysis of predictors of patient adherence to subcutaneous interferon beta-1a in MS: TRACER study: STUDYOral Gilenya (Fingolimod) or Intramuscular Interferon for Relapsing Multiple Sclerosis: STUDYSundayPlegridy approved by FDA for multiple sclerosis![]() The U.S. Food and Drug Administration (FDA) has approved Plegridy as the new multiple sclerosis treatment by Biogen Idec. Read more » Labels: Plegridy, TECFIDERA, Tysabri FDA Approves Multiple Sclerosis Drug PlegridyOn Friday, health regulators at the Food and Drug Administration (FDA) approved a new multiple sclerosis drug called Plegridy. The drug, created by Biogen Idec, is a long-acting multiple sclerosis formula that will likely replace the company’s Avonex treatment. Plegridy is meant to slow the progression of multiple sclerosis and reduce relapse rates. Read more » Biogen unveils study results confirming effectiveness of new MS treatment Plegridy
Kate Dawson, VP of Medical
Affairs at Biogen Biogen presented follow-up data from the second year of patients taking Plegridy, a once-a-month or once-every-other-week injected drug awaiting an approval decision in the U.S. as well as Europe. In the study, Plegridy was shown to continue helping patients manage relapses versus a placebo. U.S. regulators accepted Biogen’s application for approval of Plegridy last July, and recently extended its deadline to approve the drug by three months. A decision is expected in coming months. Read more » |
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||